Correlation Between Oncorus and AN2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Oncorus and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncorus and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncorus and AN2 Therapeutics, you can compare the effects of market volatilities on Oncorus and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncorus with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncorus and AN2 Therapeutics.
Diversification Opportunities for Oncorus and AN2 Therapeutics
-0.84 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Oncorus and AN2 is -0.84. Overlapping area represents the amount of risk that can be diversified away by holding Oncorus and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Oncorus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncorus are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Oncorus i.e., Oncorus and AN2 Therapeutics go up and down completely randomly.
Pair Corralation between Oncorus and AN2 Therapeutics
If you would invest 123.00 in AN2 Therapeutics on September 22, 2024 and sell it today you would earn a total of 3.00 from holding AN2 Therapeutics or generate 2.44% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Significant |
Accuracy | 4.76% |
Values | Daily Returns |
Oncorus vs. AN2 Therapeutics
Performance |
Timeline |
Oncorus |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
AN2 Therapeutics |
Oncorus and AN2 Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Oncorus and AN2 Therapeutics
The main advantage of trading using opposite Oncorus and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncorus position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.Oncorus vs. Apollomics Class A | Oncorus vs. Pyxis Oncology | Oncorus vs. Zura Bio Limited | Oncorus vs. Altamira Therapeutics |
AN2 Therapeutics vs. Aerovate Therapeutics | AN2 Therapeutics vs. Adagene | AN2 Therapeutics vs. Acrivon Therapeutics, Common | AN2 Therapeutics vs. Rezolute |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Complementary Tools
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |